TABLE 1.

Overview of Enfortumab vedotin and Erdafitinib.

Drug name	Chemical name	Structure	Main treatment	First marketed year
Enfortumab vedotin	Anti-Nectin 4 ADC ASG-22CE	C6468H10012N1720O2038S44	Advanced/metastatic urothelial carcinoma, particularly in patients previously treated with platinum-based chemotherapy and PD-1/PD-L1 inhibitors	2019
Erdafitinib	N1-(3,5-dimethoxyphenyl)-N2-isopropyl-N1-(3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl)ethane-1,2-diamine	C25H30N6O2	Advanced/metastatic urothelial carcinoma with FGFR3 or FGFR2 genetic alterations	2019